-

Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Event:

Virtual 11th Annual SVB Leerink Global Healthcare Conference

Date:

Wednesday, February 16, 2022

Time:

4:20pm – 4:50pm ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Industry:

Evolus, Inc.

NASDAQ:EOLS
Details
Headquarters: Newport Beach, CA
CEO: David Moatazedi
Employees: 150
Organization: PUB
Release Summary
Evolus announces that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.
Release Versions
English
$Cashtags
$EOLS

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Social Media Profiles
Follow us on LinkedIn
More News From Evolus, Inc.

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced “esteem”), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company’s entry into the international dermal filler market. The Estyme® collection includes four injectable HA gels that will cover a wide range of...

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2026. “We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability1 in what is seasonally our lowest revenue quarter,” said David Moatazedi, President and Chief Executive Officer of Evolus. “This performanc...

Evolus to Report First Quarter Financial Results on May 4, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks. To partic...
Back to Newsroom